Jefferies Maintains Buy on ANRO, PT Raised to $35 on Mar 16, 2026

Jefferies maintained a Buy rating on Alto Neuroscience, Inc. (ANRO) on March 16, 2026, while raising its price target to $35. This ANRO analyst rating update signals continued analyst confidence in Alto’s clinical strategy for ALTO-207. The move was logged at 10:56 AM and accompanied a reported -2.14% intraday change of $-0.53 in the stock. Investors should weigh the rating against Alto’s cash raise and clinical milestones.

ANRO analyst rating: Jefferies maintains Buy

Jefferies kept the Buy rating on ANRO and raised the price target to $35 on March 16, 2026. The firm signaled steady conviction in Alto’s lead program and valuation path while maintaining its positive stance.

Jefferies price target raise and investor impact

Raising the price target to $35 tightens the expected upside for Alto and frames near-term valuation at a higher level. For investors this means analysts see stronger midterm value, but the maintained Buy implies Jefferies expects further data or execution to drive shares higher.

ANRO price target context and market reaction

After the note, the stock moved -2.14% or $-0.53, reflecting short-term profit taking despite the PT raise. Market reaction shows traders weighed dilution risk from Alto’s recent financing against Jefferies’ revised outlook.

Historical analyst coverage for ANRO

Analyst coverage of Alto has been selective and focused on clinical catalysts and funding. Jefferies remains a notable voice in coverage, and this March action continues a pattern of few, high-conviction reports rather than broad analyst followings.

What the ANRO analyst rating means for investors

A maintained Buy with a higher price target signals confidence without increasing recommendation risk. Investors should view this as a validation of Alto’s program, not a guarantee, and balance it with the company’s cash position and trial timelines.

Market context: financing and runway impact

Alto recently announced a $120 million private placement to fund ALTO-207 through Phase 3 and potential NDA steps, which supports Jefferies’ outlook. That financing reduces immediate dilution risk and underpins the analyst’s maintained Buy stance, while investors monitor milestone execution closely Seeking Alpha

Final Thoughts

Jefferies’ March 16, 2026 ANRO analyst rating update kept Alto Neuroscience on Buy while lifting the price target to $35, a signal of continued analyst confidence in ALTO-207 and the company’s clinical roadmap. The rating is maintained rather than upgraded, so Jefferies still sees execution risk that must be proven by trial data. The $120 million private placement strengthens Alto’s cash runway and reduces near-term financing risk, supporting the analyst’s view despite a -2.14% immediate stock move. Meyka AI rates ANRO with a grade of B, which factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use this ANRO analyst rating as one input among fundamentals, clinical timelines, and your risk tolerance, noting Meyka’s grade is informational and not investment advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.